

1 **Computerized data-driven interpretation of the intrapartum cardiotocogram: a cohort**
2 **study**

3 Antoniya Georgieva*, PhD; Christopher W. G. Redman, MB, BChir, FRCP, FRCOG (ad
4 eundum); Aris T. Papageorghiou, MBChB, FRCOG

5 Nuffield Department of Obstetrics & Gynaecology, University of Oxford, Women's Centre,
6 John Radcliffe Hospital, Oxford OX3 9DU, UK.

7 *To whom correspondence should be addressed: tel.: +44 1865 857 854; email:
8 antoniya.georgieva@obs-gyn.ox.ac.uk

9

10 **Running headline:** Computerized CTG analysis in labour

11

12 **Conflicts of interest notification**

13 None declared.

14

15 **Abstract**

16 **Introduction:** Continuous intrapartum fetal monitoring remains a significant clinical
17 challenge. We propose utilising cohorts of routinely collected data. We aim to combine non-
18 classical (data-driven) and classical cardiotocography (CTG) features with clinical features
19 into a system (OxSys), which generates automated alarms for the fetus at risk of intrapartum
20 hypoxia. We hypothesise that OxSys can outperform clinical diagnosis of ‘fetal distress’,
21 when optimised and tested over large retrospective datasets.

22 **Material and Methods:** We studied a cohort of 22,790 labouring women (≥ 36 weeks
23 gestation). Paired umbilical blood analyses were available. Perinatal outcomes were defined
24 by objective criteria (Normal; Severe, Moderate or Mild compromise). We used the data
25 retrospectively to develop a prototype of OxSys, by relating its alarms to perinatal outcome,
26 and comparing its performance against standards achieved by bedside diagnosis.

27 **Results:**

28 OxSys1.5 triggers an alarm if the initial trace is nonreactive or the Decelerative Capacity (a
29 non-classical CTG feature), exceeds a threshold, adjusted for preeclampsia and thick
30 meconium. There were 187 newborns with Severe, 613 with Moderate and 3,197 with Mild
31 compromise; and 18,793 with Normal outcome. OxSys1.5 increased the sensitivity for
32 compromise detection: 43.3% vs. 38.0% for Severe ($p=0.3$) and 36.1% vs. 31.0% for
33 Moderate ($p=0.06$); and reduced the false positive rate (14.4% vs. 16.3%, $p<0.001$).

34 **Conclusions:** Large historic cohorts can be utilised to develop and optimise computerized
35 CTG monitoring, combining clinical and CTG risk factors. Our simple prototype has
36 demonstrated the principle of using such data to trigger alarms, and compares well to clinical
37 judgement.

38 **Keywords:** intrapartum fetal monitoring, computerized electronic fetal monitoring, CTG,
39 sensitivity and specificity.

40

41

42

43

44 **Abbreviations**

45 CTG – cardiotocography

46 OxSys – Oxford System for computerized intrapartum fetal monitoring

47 FD^{clin} – Operative delivery in clinical practice for the clinical diagnosis of fetal distress

48 DC – Decelerative Capacity, a computerized feature of the CTG

49

50

51 **Key Message**

52 Large historic cohorts can be utilised to develop and optimise (prior to clinical testing)
53 systems for data-driven computerized intrapartum monitoring that combine clinical and CTG
54 risk factors.

55

56 **Introduction**

57 Cardiotocography (CTG) is widely used to continuously monitor the fetus during labour but
58 its benefits are debated. Meta-analysis suggests that its routine use has a beneficial effect on
59 the incidence of neonatal seizures (1). But it does not improve rates of cerebral palsy or
60 perinatal mortality – while increasing instrumental and cesarean deliveries significantly (2).
61 On the other hand, the technique has been credited by many with reducing the rate of
62 intrapartum stillbirth: over the time that CTG was introduced intrapartum, stillbirth rates, in
63 particular those associated with intrapartum hypoxia (3), have reduced. CTG is a possible
64 cause for at least part of this improvement.

65 In this regard clinicians are trapped between two uncertainties. They are uncertain that CTG
66 helps, but equally uncertain that it does not; and reluctant to discard a well-rehearsed
67 technique with evidence from experience and basic research that it is effective, at least in
68 part.

69 Important limitations of the current practice of visual and subjective fetal monitoring include
70 a high false positive rate, which can lead to unnecessary cesarean or instrumental births (1,4);
71 and a relatively low sensitivity, such that some babies at risk are not delivered in a timely
72 fashion. Both are important, and shortcomings in labour management and CTG interpretation
73 are leading causes for healthcare litigation (5). In USA, the litigation crisis has led some to
74 suggest abandoning CTG altogether (6,7). Adjunct methods, such as fetal scalp blood
75 sampling, fetal ECG analysis (such as STAN) and pulse oximetry have shown no consistent
76 benefits (8-11).

77 The complex CTG patterns associated with fetal hypoxia are generally assessed visually;
78 these have been shown to be poorly reproducible and inconsistent (12-14). However, CTG
79 features can also be measured using computerized numerical analysis, which resolves this
80 lack of reproducibility. Intrapartum, there are computerized systems that replicate “expert
81 opinion” (15-19). In two randomised clinical trials, one showed no difference between
82 computerized and subjective analysis (18); and the results from the other (INFANT (19)) are
83 awaited. These systems merely emulate expert clinical assessment and have not been
84 optimised on data to maximise the detection of adverse perinatal outcomes / minimise the
85 false positive rate. In our opinion, computerization should go further: to use historic “big
86 data” to discover new CTG features not apparent to the eye, measure relationship to outcome,

87 estimate the effect of confounding variables; ascertain the additive effect of clinical factors;
88 and determine the background rates of CTG changes in the total population.

89 Based on this data-driven concept, we present here for the first time OxSys, an early
90 prototype system demonstrating that non-classical and classical CTG features can be
91 combined with clinical features to generate automated alarms for the fetus at risk of
92 intrapartum hypoxia. The aims are, firstly, to demonstrate how cohort data can be used as a
93 framework for development and evaluation of computerized CTG; and secondly to show how
94 this enabled us to optimise the diagnostic accuracy of our early prototype system and test it in
95 a way that is applicable to any similar CTG system.

96 **Materials and Methods**

97 *Aim 1: Creating a framework for evaluation*

98 The core composition of the Oxford archive has been described before (20,21) (Fig. 1). A
99 total of 22,790ss births (dataset *Cord gases*) were included in this study. Singleton
100 pregnancies were selected for the completeness of their CTG records acquired in routine
101 clinical practice (both external and internal fetal monitoring was included); these constituted
102 anonymized data from women in labour at 36 weeks of gestation or later, from March 2000
103 until December 2011 at the John Radcliffe Hospital, Oxford (Fig. 1). The study period ended
104 in 2011 when our unit transferred to a new clinical data collection system. Pregnancies were
105 excluded for problems that might affect the fetal responses to hypoxic stress, which would
106 need separate scrutiny, such as prematurity, congenital malformations or breech delivery
107 (Fig. 1).

108 Digitised intrapartum CTG data (sampled at 4 Hz) were archived by a central monitoring
109 system. Clinical details were derived from the Oxford Clinical Maternity database and
110 included basic maternal demographic and historical data, details of labour, delivery and
111 perinatal outcome, including umbilical cord blood samples. The latter were considered to be
112 valid if the difference between venous and arterial pH was at least 0.02 (22). The primary
113 reason for cesarean or vaginal operative delivery at the time of the intervention (if applicable)
114 was recorded electronically immediately after birth by the attending clinician. A drop down
115 menu was used allowing eight possible reasons (fetal distress, failure to progress, prolonged
116 second stage, placenta praevia, multiple birth, malpresentation, severe preeclampsia, previous
117 obstetric history). This electronic record allowed us to distinguish a clinical diagnosis of fetal

118 distress (FD^{clin}) from other reasons for operative delivery but the precise time when the
119 decision for operative delivery was taken, was not documented electronically. Only the
120 records with validated cord gas analyses were included in this study (Fig. 1).

121 All CTG records, archived on our server were available for this retrospective analysis. For
122 each woman, the entire CTG record was analysed. Those stopped three hours or more before
123 delivery were excluded, because they could have little relevance to the analysis of features
124 leading to obstetric intervention and/or affecting the condition of the baby at birth. Short
125 fragments of CTG traces, less than 15 minutes long, were also excluded. Most traces (80%)
126 ended less than five minutes before birth, with 93% ending less than 20 minutes and only 2%
127 ending longer than 60min before birth.

128 Perinatal outcomes were classified into four exclusive groups (Table 1), defined
129 pragmatically. Severe adverse outcome was defined as a composite outcome while . moderate
130 and mild adverse outcomes were defined by the degree of acidemia in umbilical arterial
131 blood.

132 We established when operative delivery was for FD^{clin} in each of the outcome groups. In
133 parallel, retrospective occurrences of OxSys1.5 alarms were defined, which enabled us to
134 compare OxSys to clinical management in terms of:

- 135 - The detection rates of different groups of adverse outcomes.
- 136 - The false positive rate, that is the comparative rates of positive tests associated with
137 normal outcomes.
- 138 - A “dose-response” effect, i.e. whether an increasing number of alarms or
139 interventions were observed in the outcomes with worsening compromise from Mild
140 to Severe.

141 The framework we present is a method whereby computerized CTG analysis systems could
142 be tested on a comprehensive database of unselected cases, which includes paired cord blood
143 gas analyses at birth and, crucially, prospectively collected classification of the reasons for
144 operative delivery during labour. The framework allows the likely utility of computerized
145 CTG analysis systems to be evaluated; and allows calculation of effect size, sensitivity, false
146 positive rates and potentially sample size to be estimated prior to prospective evaluation. In

147 this report we give the proof of principle of this method by evaluating our own computerized
148 CTG system (an early prototype). This is described in Aim 2.

149 *Aim 2: Applying the methodology to establish a prototype system for computerized*
150 *intrapartum CTG analysis.*

151 We assessed an early prototype computerized CTG system (The Oxford System, OxSys 1.5).
152 The CTG is analysed in 15min windows; these move forward every five minutes, when the
153 analysis is updated, on the basis of being a clinically relevant rate. This continues until an
154 alarm is triggered or delivery, whichever occurs first. OxSys 1.5 is largely based on one
155 computerized parameter – the decelerative capacity (DC) of Phase Rectified Signal
156 Averaging (23-25). ‘Decelerative capacity’ analyses the entire fetal heart rate signal within
157 the 15 minute analysis window, including accelerations and decelerations. It provides an
158 average measure of downward movements in the fetal heart rate. Lower values are measured
159 in a normal trace without significant decelerations. If the trace has many accelerations, these
160 increase the DC but it remains well within the normal range (2bpm to 4bpm, data not shown).
161 However, DC increases significantly if there are deep, steep-sloped and/or frequent
162 decelerations. In effect, DC is a measure that combines both the time the trace spends at
163 baseline and the frequency and depth of decelerations. Non-reactive traces have very low DC.
164 DC has been confirmed to increase at the time of induced cord occlusion in the fetal lamb
165 model of intrauterine hypoxic-ischaemic stress (24). The specific DC parameters were set as
166 in our previous work (23). Based on an iterative process that uses both clinical knowledge
167 and mathematical optimisation (26,27), we established the current system configuration
168 (OxSys 1.5): a single OxSys alarm is triggered if: (1) the first hour of the trace is flat and
169 non-reactive (DC value below 1bpm without accelerations, (28)); or (2) the DC reaches a
170 defined threshold at any point during labour. The threshold is adjusted to a lower value if
171 there is thick meconium or preeclampsia or to a higher value otherwise. A single OxSys
172 alarm is required in order for us to count the alarm as a true or false positive.

173 Only CTG segments with valid signal in at least 50% of the time (signal quality) and only
174 alarms that occurred 15 minutes or longer before the time of birth were considered. This is
175 because alarms triggered nearer to the time of delivery would have been ‘too late’ to
176 influence management.

177 The study was approved by the Newcastle & North Tyneside 1 Research Ethics Committee,
178 REC reference 11/NE/0044 (data before 2008) and the South Central Ethics Committee, REC
179 reference 13/SC/0153 (data beyond 2008). Informed consent was not required.

180 **Results**

181 The demographic characteristics of the women are reported in Table 2. The dataset *Cord*
182 *gases* (included in our analysis in this study) had a higher rate of operative deliveries than the
183 cohort from which it was derived, *Birth indication* (all monitored deliveries in March 2000-
184 December 11). Also, slightly more babies showed thick meconium.

185 Dataset *Cord gases* includes 187 babies with Severe compromise. The clinical sensitivity or
186 ability to detect Severe compromise during labour is 37.97% (Table 3). Thus, this project has
187 enough power ($\alpha=0.05$, $\beta=0.1$, two-sided Wald test) to detect significantly higher sensitivity
188 for OxSys at 50% or above.

189 The size of the database is crucial for reliable estimation of the rate of OxSys alerts in
190 Normals (false positive rate). A decrease in false positive rate of $\geq 0.7\%$ can be detected in
191 *Cord gases* ($\alpha=0.05$, $\beta=0.1$, two-sided Wald test), compared to the estimated rate of clinical
192 intervention in Normal – 16.33% (Table 3).

193 *Optimisation and diagnostic accuracy of current prototype (OxSys1.5)*

194 We utilised the above framework to iteratively develop a diagnostic system prototype
195 (illustrated in Fig. 2): we began with a very simple prototype: one triggering an alarm if at
196 any point the DC passed a single threshold (5.8bpm). After further experiments, we
197 established that the sensitivity for severe compromise can be improved (without worsening
198 the false positive rate) if the DC threshold was lowered to 4bpm in the presence of thick
199 meconium or preeclampsia, which are well known clinical risk factors, and increased to
200 6.8bpm otherwise. These thresholds were selected after optimisation on the data.
201 Furthermore, we established that the sensitivity to severe compromise was increased further
202 if an alarm was also triggered in the rare cases where the initial CTG trace was nonreactive
203 (Fig. 2).

204 The sensitivities of detecting Severe, Moderate or Mild adverse outcomes both by clinical
205 assessment and OxSys1.5 are presented in Table 3. The detection rates for compromise types
206 were consistently in favour of OxSys1.5 but the differences were statistically significant only

207 if Severe and Moderate compromise were combined into one category: 32.6% vs. 37.8%, Chi
208 squared test, $p=0.03$.

209 The false positive rates can be measured in the Normal outcome group, in whom a clinical
210 decision was taken to intervene (FD^{clin}) or the computerized system caused an “alarm”. Here
211 the respective figures were 16.3% for FD^{clin} and 14.5% for OxSys1.5, ($p<0.001$)

212 Thus OxSys1.5 is associated with comparable or higher sensitivity and significantly lower
213 false positive rates when compared to clinical diagnosis. A dose-response relationship was
214 demonstrated for both FD^{clin} and OxSys: there was an increasing rate of alarms from Normal
215 through Mild and Moderate to Severe. Furthermore, the rates of both FD^{clin} and OxSys alarms
216 declined with increasing pH threshold, in parallel, with OxSys alarm rates being consistently
217 higher (Fig. 3), demonstrating a dose-response relationship.

218 An important aspect of intrapartum CTG is the degree of urgency of delivery when the
219 monitoring is abnormal. Only carefully conducted prospective studies can show how useful
220 the system is in this regard. We can retrospectively determine how long before birth an alarm
221 would have been triggered by OxSys (the Alarm to Delivery (A-D) interval). This interval
222 must be long enough to allow time for operative delivery. The minimal acceptable A-D
223 interval depends on the clinical context, e.g. whether the woman is in the second stage of
224 labour.

225 The results reported in Table 3 of our manuscript used an A-D of 15 minutes. However we
226 also investigated varying A-D intervals (from 0 to 60min) and stratified the analysis
227 according to the labour stage. In the first stage of labour, the performance of OxSys would
228 have been similar if the A-D interval had been 60min. However, in the second stage of
229 labour, the alarm rates quickly reduced as the A-D interval rose from 0min to 60min: only
230 45% of alarms in the second stage were raised 45min or more before birth, and 25% were
231 raised 60min or earlier. Hence an alarm in the first stage of labour in most instances gave a
232 reasonable warning time of at least 60 minutes; the shorter warning time in the second stage
233 of labour is to be expected and is not necessarily incompatible with timely intervention.

234 Overall, regardless of labour stage, around 40% of OxSys alarms in babies with Severe
235 compromise and about 20% in those with Moderate, were triggered more than five hours prior
236 to birth.

237 **Discussion**

238 We describe for the first time a methodology with which computerized CTG interpretation
239 can be evaluated and compared to clinical assessment, using the same historic cohort data and
240 identical measures of diagnostic accuracy. In this retrospective study, operative delivery was
241 used to expedite delivery because of fetal distress (FD^{clin}) in 37.97% of cases with Severe
242 adverse outcome and in 31.00% of those with Moderate. The rate of unnecessary intervention
243 due to fetal distress was, as is generally believed, very high: over 16% interventions in the
244 Normal group (a third of these were Caesareans and two thirds were vaginal operative
245 deliveries). The simple prototype system presented here (OxSys1.5) already performed at
246 least as well, if not slightly better, than clinical assessment (both in terms of higher sensitivity
247 and lower false positive rate). In future work, we will adopt the framework and iterative
248 development process illustrated here (Fig. 2), to define additional rules for triggering alarms.
249 These will be added to OxSys to ensure a significantly better system prototype with
250 substantially higher clinical utility.

251 The strengths of this study include our large cohort of high quality detailed data. We also
252 considered various perinatal outcomes and the effects of different arterial pH thresholds (Fig.
253 3). Our data spans years and clinical practice has inevitably changed in that time. However,
254 there was no evidence of any temporal change to the performance of OxSys during the study
255 period (data not shown). Furthermore, a system that works well on a cohort spanning years of
256 varying clinical practice, will be better positioned to work well on new data, than one
257 designed with data from a narrow snapshot of clinical practice.

258 Retrospective data to evaluate methods for CTG have been previously used (18,34). The
259 performance of PeriCALM (marketed by PeriGen), which simulates clinical expert
260 assessment has been reported (34). However, the cases were selected based on being either
261 severely compromised or with no signs of acidosis. Hence, a valid false positive rate is not
262 available. In another study of >8000 deliveries the sensitivity of significant ST events from
263 STAN monitoring (Neoventa Medical), (18) to predict arterial $pH < 7.05$ was found to be
264 44.4%; this is higher than in our study (37.3% for OxSys) but at a higher alarm rate for all
265 babies with arterial $pH \geq 7.05$ of 19.2% for STAN (16.1% for OxSys). It must be remembered
266 that for STAN, accurate evaluation of CTG is also necessary, and combining STAN with
267 OxSys is an interesting future possibility.

268 There are also inherent limitations and considerations, which are valid for any work with
269 intrapartum CTG analysis:

270 Firstly, retrospective studies have inherent biases, and these can affect analysis of CTG data
271 (30). A higher false positive rate and lower sensitivity is expected in populations with lower
272 prevalence of compromise, but the proposed diagnostic methods are still valid, because the
273 basic pathophysiological relationship between CTG patterns and compromise is universal.

274 Secondly, there is a ‘treatment paradox’: if perinatal compromise has been prevented by
275 appropriate intervention, it could present as a false positive – a wider problem in obstetrics
276 discussed recently (31). In this context, cord blood gas analyses and our definitions of
277 outcome are important: it is reasonable to assume a false positive intervention in the absence
278 of acidemia (the Normal group, (32)). However, if there is moderate acidemia, the outcome
279 could be placed in a category of a prevented true positive (i.e. Moderate or Mild
280 compromise).

281 Thirdly, the condition of the baby at birth cannot be known at the time the decision to deliver
282 is made using CTG (neither in current clinical practice or with computerized alarms). The
283 CTG is fundamentally limited in its ability to ‘predict’ intrapartum hypoxia – it is only a
284 surrogate marker of measurements that we have no access to (for example fetal blood
285 pressure, fetal cerebral perfusion, fetal oxygenation, etc.). However, in the absence of such
286 direct measures, a ‘risk assessment’ approach by identifying a group of fetuses at increased
287 risk of compromise, needs to be taken.

288 There are conflicting views as to whether acidemia alone is a valid endpoint of CTG and
289 clinical obstetrics (30) prompting the need to define separate severe and moderate
290 compromise groups. However, not all severe compromises have an intrapartum cause and are
291 preventable by CTG monitoring: the fact that it cannot often be established whether a baby’s
292 injury was due to labour and/or preventable, is a wider challenge in clinical practice,
293 litigation and CTG research. Therefore, we have kept an open mind about the aetiology of
294 perinatal cerebral injury and proposed one overarching study design, by focusing on both
295 clinically important severe compromise and different grades of acidemia. Our definitions of
296 perinatal outcomes (Table 1) are based in part on umbilical arterial blood gas measurements
297 at birth. Although there is no consensus as to how acidemia is best measured we have
298 previously demonstrated that pH is preferable to Base Deficit (BD) (21). Moreover, in our
299 study, 96% of the newborns with $\text{pH} < 7.05$ had a $\text{BD} > 10 \text{mmol/l}$ and 85% $> 12 \text{mmol/l}$. In Fig.
300 3, we demonstrate the effect of changes in pH thresholds, which amounts to a graded (and
301 mechanistically reasonable) dose response effect.

302 Finally, CTG recordings during labour often may have poor quality leading to
303 misinterpretation and uncertainty. This is a problem both in visual and computerized CTG
304 interpretation. There are further limitations of the techniques for CTG acquisition, with
305 rounding off errors and lack of ‘true’ beat to beat detailed data (as available in adult heart rate
306 analysis).

307 All of the above limitations are inherent to CTG monitoring in clinical practice and our study
308 does not claim to resolve these. Instead, our work proposes that further progress is possible
309 despite these limitations and we propose to develop future OxSys versions with these
310 considerations in mind.

311 At this stage, our early prototype has limited clinical utility. But we advocate the future
312 development of refined systems using our framework to allow objective, standardised
313 reporting and comparison between the diagnostic accuracies of different methods for CTG
314 interpretation. Further work will examine the patterns of those fetuses with Severe
315 compromise that were unrecognized and of those that triggered false alarms, generating new
316 hypotheses about important CTG patterns. Any new hypotheses can be rapidly tested using
317 the data leading to an iterative development of scientific, evidence-based methods for CTG
318 interpretation. This means that computerized CTG can be extensively optimised before
319 expensive clinical trials. In this regard validation on different independent datasets is
320 essential prior to prospective clinical testing.

321 **Funding**

322 AG is funded by a generous research grant from Action Medical Research and the Henry
323 Smith Charity.

324 **References**

- 325 1. Dyson Ch, Austin T. Lees Ch, Could routine cardiotocography reduce long term
326 cognitive impairment? *BMJ* 2011;342:d3120.
- 327 2. Alfirevic Z, Devane D, Gyte GM. Continuous cardiotocography (CTG) as a form of
328 electronic fetal monitoring (CTG) for fetal assessment during labour. *Cochrane Database*
329 *Syst Rev.* 2013 May 31;5:CD006066.
- 330 3. Walsh CA, McMenamain MB, Foley ME, Daly SF, Robson MS, Geary MP. Trends in
331 intrapartum fetal death, 1979-2003. *Am J Obstet Gynecol.* 2008 Jan;198(1):47.e1-7.

- 332 4. Vogel et al 2015. WHO Multi-Country Survey on Maternal and Newborn Health
333 Research Network. Use of the Robson classification to assess caesarean section trends in
334 21 countries: a secondary analysis of two WHO multicountry surveys. *Lancet Glob*
335 *Health*. 2015 May;3(5):e260-70.
- 336 5. The NHS Litigation Authority. Ten years of maternity claims: an analysis of NHS
337 Litigation Authority data 2012.
- 338 6. Sartwelle TP. Electronic Fetal Monitoring: A Defense Lawyer's View. *Rev Obstet*
339 *Gynecol*. 2012;5:e121-5.
- 340 7. Grimes DA, Peipert JF. Electronic fetal monitoring as a public screening program: the
341 arithmetic failure. *Obstet Gynecol*. 2010;116(6):1297-400.
- 342 8. Olofsson P, Ayres-de-Campos D, Kessler J, Tendal B, Yli BM, Devoe L. A critical
343 appraisal of the evidence for using cardiotocography plus ECG ST interval analysis for
344 fetal surveillance in labour. Part I: the randomized controlled trials. *Acta Obstet Gynecol*
345 *Scand*. 2014;93:556-8.
- 346 9. Saade G. Fetal ECG analysis of the ST segment as an adjunct to intrapartum fetal heart
347 rate monitoring: a randomized clinical trial. *Am J Obstet Gynecol*. 2015;212:S2-S2 .
- 348 10. Chandrachan E. Fetal scalp blood sampling during labour: is it a useful diagnostic test or
349 a historical test that no longer has a place in modern clinical obstetrics? *BJOG*.
350 2014;121:1056-60.
- 351 11. East CE, Begg L, Colditz PB, Lau R. Fetal pulse oximetry for fetal assessment in labour.
352 *Cochrane Database Syst Rev* Oct 7;10:CD004075 2014.
- 353 12. Devane D, Lalor J. Midwives' visual interpretation of intrapartum cardiotocographs:
354 intra- and inter-observer agreement. *J Adv Nurs*. 2005 Oct;52(2):133-41.
- 355 13. Rhöse S, Heinis AM, Vandenbussche F, van Drongelen J, van Dillen J. Inter- and intra-
356 observer agreement of non-reassuring cardiotocography analysis and subsequent clinical
357 management. *Acta Obstet Gynecol Scand*. 2014 Jun;93(6):596-602.
- 358 14. Chauhan SP, Klauser CK, Woodring TC, Sanderson M, Magann EF, Morrison JC.
359 Intrapartum nonreassuring fetal heart rate tracing and prediction of adverse outcomes:
360 interobserver variability. *Am J Obstet Gynecol*. 2008;199:623.e1-5.

- 361 15. Keith RDF, Beckley S, Garibaldi JM, Westgate J, Ifeachor EC, Greene KR. A multicentre
362 comparative study of 17 experts and an Intelligent computer system for managing labour
363 using the cardiotocogram. *BJOG*. 1995;102:688-700.
- 364 16. Elliot C, Warrick PA, Graham E, Hamilton EF. Graded classification of fetal heart rate
365 tracings: association with neonatal metabolic acidosis and neurologic morbidity. *Am J*
366 *Obstet Gynecol*. 2010;202:4258.e1-8.
- 367 17. Costa MA, Ayres-de-Campos D, Machado A, Santos CC, Bernardes J. Comparison of a
368 computer system evaluation of intrapartum cardiotocographic events and a consensus of
369 clinicians. *J Perinat Med*. 2010;38:191-5.
- 370 18. Nunes I, Ayres-de-Campos D, Ugwumadu A, Amin P, Banfield P, Nicoll A et al. for the
371 FM-ALERT study group. FM-ALERT: a randomised clinical trial of intrapartum fetal
372 monitoring with computer analysis and alerts versus previously available monitoring
373 [abstract], ECIC'15, Porto, Portugal (2015).
- 374 19. INFANT clinical trial protocol [internet, cited 2015 Oct 07]. Available from
375 <http://www.ucl.ac.uk/cctu/researchareas/womenshealth/infant/information-for-clinicians>.
- 376 20. Georgieva A, Payne SJ, Moulden M, Redman CW. Relation of fetal heart rate signals
377 with unassignable baseline to poor neonatal state at birth. *Med Biol Eng Comput*. 2012
378 Jul;50(7):717-25.
- 379 21. Georgieva A, Moulden M, Redman CWG. Umbilical cord gases in relation to the
380 neonatal condition: the EveREst plot. *Eur J Obstet Gynaecol Reprod Biol*. 2013;168:155-
381 60.
- 382 22. Armstrong L, Stenson BJ. Use of umbilical cord blood gas analysis in the assessment of
383 the newborn. *Archives of Disease in Childhood Fetal and Neonatal* 2007;92:F430-4.
- 384 23. Georgieva A, Papageorghiou AT, Payne SJ, Moulden M, Redman CWG. Phase rectified
385 signal averaging for intrapartum electronic fetal heart rate monitoring is related to
386 acidaemia at birth. *BJOG*. 2014;128:889-94.
- 387 24. Rivolta MW, Stampalija T, Casati Dm Richardson BS, Ross MG, Frasch MG, Bauer A,
388 Ferrazzi E, Sassi R. Acceleration and deceleration capacity of fetal heart rate in an in-vivo
389 sheep model. *PLoS One* 2014;9(8):e104193.

- 390 25. Advances in computing are driving progress in fetal monitoring, A. Georgieva. *British*
391 *Journal of Obstetrics and Gynaecology* Dec 25, 2015 DOI: 10.1111/1471-0528.13725.
- 392 26. *Optimization in Medicine*, eds. CJS Alves, PM Pardalos, LN Vicente, Springer 2008;
- 393 27. *Optimization in Medicine and Biology*, eds. GJ Lim and EK Lee, Auerbach Publications
394 2008
- 395 28. Georgieva A, Ugwumadu A, Papageorghiou AT, Redman CWG. Significance of the first
396 hour of the fetal heart rate monitoring: nonreactive vs reactive initial trace, *European*
397 *Congress on Perinatal Medicine*, Maastricht, 2016.
- 398 29. Yudkin PL, Aboualfa M, Eyre JA, Redman CW, Wilkinson AR. New birthweight and
399 head circumference centiles for gestational ages 24 to 42 weeks. *Early Hum Dev* 1987;
400 15(1): 45–52.
- 401 30. Cahill AG and Macones GA. Fetal heart rate tracings and neonatal metabolic acidosis:
402 Elliott et al, *Am J Obstet Gynecol.* 2010;202:317-18.
- 403 31. F. Cheong-See, J. Allotey, N. Marlin, B.W. Mol, E. Schuit, G. ter Riet, R.D. Riley,
404 K.G.M. Moons, K.S. Khan and S. Thangaratinam. Prediction models in obstetrics:
405 understanding the treatment paradox and potential solutions to the threat it poses. *BJOG*
406 published online: 25 Jan 2016 DOI: 10.1111/1471-0528.13859.
- 407 32. ACOG Task Force on Neonatal Encephalopathy, *Neonatal encephalopathy and*
408 *neurologic outcome*, second edition (2014).
- 409 33. A. Bhide, E. Chandrachan, and G. Acharya. Fetal monitoring in labor: Implications of
410 evidence generated by new systematic review. *Acta Obstet Gynecol Scand* 95, 5-8 (2015).
- 411 34. Elliot C, Warrick PA, Graham E, Hamilton EF. Graded classification of fetal heart rate
412 tracings: association with neonatal metabolic acidosis and neurologic morbidity. *Am J*
413 *Obstet Gynecol.* 2010;202:4258.e1-8.
- 414

415

416

417 **Tables**

418 Table 1. Definitions of the outcome groups and incidence in the dataset included in analysis.

Exclusive outcome groups		Data included in this study: dataset <i>Cord gases</i>, n = 22,790
Severe	Composite outcome of: stillbirth; neonatal death; neonatal encephalopathy; intubation or cardiac massage followed by admission to neonatal intensive care for ≥ 48 hrs.	187 (0.82%)
Moderate	Umbilical cord arterial pH < 7.05 without severe compromise	613 (2.69%)
Mild	$7.05 \leq \text{pH} < 7.15$ without severe compromise	3,197 (14.03%)
Normal	pH ≥ 7.15 without severe compromise	18,793 (82.46%)

419

420

421 Table 2. The Oxford datasets: clinical and demographic characteristics: *n* (%). The datasets
 422 are defined in Fig. 1.

	<i>All</i> (58,748)	<i>Birth indication</i> (38,818)	<i>Cord gases</i> (22,790)
Nulliparous	32,523 (55.36%)	21,927 (56.49%)	13,948 (61.20%)
Pre-eclampsia	6,303 (10.73%)	3,497 (9.00%)	2,282 (10.01%)
Gestational Diabetes	509 (0.87%)	423 (1.09%)	262 (1.15%)
Induction of labour	25,157 (42.82%)	17,966 (46.28%)	10,838 (47.56%)
Cesarean or Forceps/Ventouse delivery	22,432 (38.18%)	15,594 (40.17%)	11,382 (49.94%)
Cesarean	7,080(12.05%)	5,164 (13.30%)	3,908 (17.15%)
Thick meconium	4,531 (7.71%)	3,437 (8.85%)	2,474 (10.86%)
Oxytocin	22,062 (37.55%)	15,295 (39.40%)	9,783 (42.93%)
Low Apgar	1,448 (2.47%)	1,008 (2.60%)	782 (3.43%)
Severe compromise	473 (0.81%)	255 (0.66%)	167 (0.79%)
Convulsions	109 (0.18%)	74 (0.19%)	50 (0.22%)
Neonatal encephalopathy	164 (0.28%)	80 (0.20%)	51 (0.22%)
Intubation or cardiac massage	614 (1.05%)	318 (0.82%)	247 (1.08%)
SCBU admission \geq 48hrs	2,910 (3.25%)	1,215 (3.13%)	811 (3.56%)
Small baby (<3rd centile§)	936 (1.59%)	575 (1.48%)	346 (1.52%)
Large baby (>97th centile§)	2,922 (4.97%)	1,953 (5.03%)	1,282 (5.64%)

Stillbirth	2 (0.0034%)	1 (0.0026%)	0 (0.00%)
Neonatal death (<28 days)	30 (0.05%)	22 (0.06%)	17 (0.07ss%)

423 § adjusted Yudkin (29) centile.

424

425

426

427 Table 3. OxSys1.5 alarm rate and emergency deliveries in clinical practice due to fetal

428 distress (FD^{clin}): number (%) [95% confidence interval].

Diagnostic accuracy on <i>Cord gases</i> dataset ($n=22,790$)				
Exclusive outcome groups	Compromise (<i>sensitivity</i>)			Normal (<i>false positive rate</i>)
	Severe	Moderate	Mild	
Number of births	187	613	3,197	18,793
Detected in clinical practice (FD ^{clin})	71 (37.97%) [31.0%-44.9%]	190 (31.00%) [27.3%-34.7%]	719 (22.49%) [21.0%-23.9%]	3,068 (16.33%)* [15.8%-16.9%]
Detected by OxSys 1.5	81 (43.32%)** [36.2%-50.4%]	221 (36.05%)** [32.2%-39.9%]	789 (24.68%)† [23.2%-26.8%]	2,710 (14.42%)‡ [13.9%-14.9%]

429

430 * 906 (29.5%) of these were Cesarean sections;

431 Chi squared test, OxSys 1.5 vs. Clinicians: ** $p = 0.29$; *** $p = 0.06$; † $p < 0.04$; ‡ $p < 0.001$.

432

433

434

435

436 Figures


437

438 Fig. 1. Data flow chart. – in separate pdf.


439

440

441



442
 443 Fig. 2. OxSys evolution throught the iteration phases: the sensitivity of the system improved
 444 significantly ($p < 0.001$) without increasing the false positive rate, *Cord gases* dataset ($n =$
 445 22,790).



446

447 Fig. 3. The rate of emergency interventions for fetal distress (FD^{clin}) and the OxSys1.5 alarm
448 rate (i.e. the sensitivity) consistently increase if lower pH threshold is used to define
449 increasing acidemia, *Cord gases* dataset ($n = 22,790$).
450